Notice of Denial of Medicare Prescription Drug Coverage (CMS-10146)
No material or nonsubstantive change to a currently approved collection
No
Regular
Approved without change
03/13/2023
03/02/2023
Prior to the re-submission of the information collection âNotice of Denial of Medical Coverage (or Payment) (NDMCP) (CMS-10003)â (0938-0829), the agency will evaluate the burden, usability, and clarity of the forms and appeals process. This evaluation will be guided by the principles and priorities set forth in the memorandum titled âImproving Access to Public Benefits Programs Through the Paperwork Reduction Actâ (April 13, 2022) https://www.whitehouse.gov/wp-content/uploads/2022/04/M-22-10.pdf. The assessment will inform and be integrated in the agencyâs next submission of this information collection.
table that charts list comparision
Inventory as of this Action
Requested
Previously Approved
06/30/2024
06/30/2024
06/30/2024
2,627,898
0
2,627,898
656,975
0
656,975
0
0
0
Pursuant to 42 CFR 423.568(e) and (f), if a Part D plan denies drug coverage it must give the enrollee written notice of the adverse coverage determination. The form and content of the written denial notice must comport with specific requirements, including a description of the appeals process.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.